Clinical Trials
5
Active:0
Completed:0
Trial Phases
3 Phases
Phase 2:2
Phase 3:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (40.0%)Phase 2
2 (40.0%)Phase 3
1 (20.0%)Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
Not Applicable
Not yet recruiting
- Conditions
- NSCLC Brain Metastasis
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 200
- Registration Number
- NCT06716775
A Phase 1b Study of TTF in Combination With Durvalumab and GemCis in BTC.
Not Applicable
Recruiting
- Conditions
- Biliary Tract Cancers (BTC)
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 60
- Registration Number
- NCT06611345
- Locations
- 🇨🇳
Anhui Provincial Hospital, He Fei, China
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Phase 2
Recruiting
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 30
- Registration Number
- NCT06353360
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, China
Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Device: Tumor treating fields（EFE-P100）
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2022-12-22
- Target Recruit Count
- 348
- Registration Number
- NCT05661240
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Phase 3
Recruiting
- Conditions
- Locally Advanced Pancreatic Cancer
- Interventions
- Device: Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-03-24
- Target Recruit Count
- 512
- Registration Number
- NCT05653453
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
News
No news found